Introducing: Pluri

Cells are the very fabric of our universe: Everything in this world begins and ends with cells. Technology that harnesses the innate power of cells, and their ability to expand rapidly, therefore has the potential to change the world.

We are thrilled to share a new part of our journey: our recent official name change from Pluristem to Pluri. The very definition of the word explains our new vision. “Pluri” means more, and we look forward to offering more solutions for more industries, enabled by our innovative 3D cell expansion technology platforms.

Pluri’s platforms are the new gold standard to accelerate development of cell-based solutions that will improve global quality of life and promote sustainability in a wide range of fields.

Our new business development strategy is twofold:

First, we are relying on our innovative technology to create new, revolutionary products. These cell-based products are developed to address some of the world’s most pressing issues, from sustainability to sustenance.

Second, we continue to search for partnerships that leverage our most valuable asset—that is, our technology. With this proprietary technology and with new partners at hand, we can innovate in many verticals, from cultured meat to therapeutics to agriculture technology and beyond.

Pluri pushes the boundaries of science to engineer groundbreaking cell-based products that promote global wellbeing and sustainability.

We look forward to welcoming the new era of Pluri and realizing our ambitious vision.


From food to pharma, Pluri improves lives today

We are now leveraging our advanced cell expansion platforms and our position as a worldwide leader in cell technology to develop, manufacture and market high quality cell-based products.

Revolutionizing food

Earlier this year, we entered a landmark collaboration with Israeli food giant Tnuva to produce cell-based meat, with our technology at the heart of the partnership.

This first joint venture in our food tech vertical is set to bring sustainable, affordable cultured food to consumers across the globe, creating its first product as soon as next year. We are uniquely poised to power the full production chain for the development and manufacture of affordable, quality cultured food.

Our partners at Tnuva believe so as well. “We chose to collaborate with Pluri (formerly Pluristem) because we believe it owns one of the most advanced cell production technologies in the world,” said Eyal Malis, CEO of Tnuva Group.

Transforming health and medicine

Since 2003, Pluri has perfected methods to expand a single placenta cell into billions of distinct cells. The cell expansion process serves to develop groundbreaking cell-based therapies that solve some of medicine’s most urgent unmet needs.

Pluri’s technology accelerates the development and approval of more targeted, personalized, and well-tolerated allogeneic treatments, with no need for genetic matching – changing the face of medicine, one cell at a time.


Partnership opportunities in the future

We see the potential in sharing this technology, not just the products that it creates.

Our new approach is one that highlights collaboration. Strategic partnerships and investments across different verticals can help to expedite the research, development and commercialization phase of many types of cell-based products. A collaborative approach also ensures that an expert in their respective field will drive key business decisions from decades of expertise.

Plurinuva is just the first partnership in our vertical of Plurifood. Looking ahead, we hope to continue to develop various cultured food products through partnerships.

We also aim to collaborate with companies from industries that include—but are not limited to—agriculture, biotech, and cell biology.


Our commitment to sustainability

As we move forward into the new era of Pluri, we are excited to continue our dedication to Environmental and Social Governance. Our new strategy will chart a more sustainable path in many different sectors of business and technology, from patient care to animal agriculture.

How does Pluri benefit the environment?

Meat cultured from cells in a laboratory setting has the potential to reduce greenhouse gases and other crucial resources by an incredible amount. Cultured meat produced using renewable energy reduces global warming impacts by up to 92 percent and reduces land use by up to 95 percent.

In a global age of overpopulation and dwindling finite resources, these environmental benefits are huge. Cultured meat is set to disrupt the global meat market.

How can Pluri promote better health and wellbeing?

Originating from the highest quality, premium cells, cultured meat could easily become the tastier and more nourishing option.

When it comes to healthcare, Pluri’s innovative therapies may offer hope to sick patients without another avenue for treatment. Our new cell therapy candidate can both give patients with bone marrow failure a chance for a better recovery and treat radiation exposure.

The potential impact on livelihood with just one cell candidate can be far-reaching, and this sentiment is true for Pluri’s products across the board. All Pluri’s cell therapies are created with people as the first consideration, meant to improve quality of life for patients in hospitals and those in recovery.


We are Pluri.

Our patented technology harnesses the wisdom of nature to develop and manufacture next generation cell-based products across a range of fields.

We aim to pioneer a biotech revolution to create next-generation cell-based products that improve human wellbeing, increase sustainability, and advance solutions to humanity’s greatest challenges.

We are thrilled to welcome you on our journey.

We only have one earth.

This is why we at Pluri are committed to creating a better planet on World Environment Day and every day.
These campaigns are important to shine a spotlight on our global footprint. To ensure we as a company and as individuals look and reflect on how we are taking action to make a difference to protect our planet and live sustainably. This is where technology is essential to enable this transformative change and support individuals as they commit to a better sustainable way of life. Whether that means going vegetarian or choosing electric cars to drive to work. These changes can only happen with technology supporting the way.

For us at Pluri, this is where we believe our cell-based technology platform can play a huge role to help transform industries towards environmental improvements.

Pluri’s technology can expand any cell type

Today, our PLacental eXpanded (PLX) cell therapies have treated hundreds of patients worldwide with a strong safety profile, demonstrated in the field of regenerative medicine. Yet, the power of our state-of-the-art cell-based manufacturing platform is not just limited to placental cells. Harnessing cutting-edge technologies in cell culture, tissue engineering and bioprocessing, our technology has the potential capabilities to expand and optimize cells of any type.

This opens up new possibilities to apply our technology to foodtech, agtech and other industries, where we can enable the mass-scale production of high-quality animal and plant cells with batch-to-batch consistency. The recent signing of our landmark food-tech joint venture with Tnuva Group, Israel’s largest food producer, to establish a cultured food platform, is one example of the work underway.

As humans and animals use more resources and generate more waste than ever before, our technology brings great promising implications to help protect our environment.

In the last decade, there have been huge technological advances in the food tech industry. One of these is the development of cultured meat (genuine animal meat that is produced by cultivating animal cells directly). Pluri’s cell expansion technology can be directly applied to develop cell-based meat and plant products that would have flavor similar to conventional food. This would bring huge environmental benefits.

The influence of conventional farming on our environment today

Besides the humane aspects associated with the rearing and slaughtering conditions of animals in the food industry, the livestock industry today impacts our environment in many ways.

In fact, the biggest challenge facing the industry, and as a result our environment, is from the ever-increasing consumption of animal products. Global meat production is expected to double from 229 million tons in 1999 to 465 million tons by 2050[1]!

This will have a huge impact on carbon dioxide emissions – one research paper estimates that the global livestock industry is responsible for at least 51% of the greenhouse gases emitted to the atmosphere. Furthermore, the increasing demand for animal products and the lack of land has caused the livestock industry to become the main cause for clearing forests and turning them into pasture. Production of animal food products is also the greatest agricultural cause of water pollution alongside bringing huge water wastage and the production of copious amounts of waste[2].

When we consider arable farming, a similar picture is seen. Intensive feed-crop production can lead to severe land degradation, water pollution and biodiversity losses, while expanding arable land into natural ecosystems also can have serious ecological consequences. These include the loss of biodiversity and of ecosystem services such as water regulation and erosion control. The use of fertilizers and pesticides also contaminate and degrade the environment.
But what if we could change this?

This is exactly where we believe the power of cell-based technologies, like Pluri’s, can inspire and transform.

How do cell-based meats and plants help the environment?

As our population grows, the foodtech and agtech industry must create a sustainable system that can feed the world in a way that is scalable, efficient, cost effective, and does not harm the environment.

Cell-based meat production (or cellular agriculture) provides the industry with one solution. Though large-scale cell-based meat production technologies are just getting started, the outlook is highly promising.

Two recent studies suggest that cell-based meat could cause up to 92% less global warming, 93% less air pollution and use up to 95% less land and 78% less water compared to conventional beef production.

So let’s imagine a future in which cell-based meat or plant production becomes the major source of protein. What would our world be like and how could this benefit our environment?

With less animals needing to be slaughtered, greenhouse gas emissions would be anticipated to fall, alongside less land and water used. This could also free up cropland to feed more people. This land could even be used for ecological purposes to aid reforestation for carbon sequestration or to replant. Here the capabilities of plant roots to absorb water can be used to help prevent the cycle of drought, flooding, and erosion that occurs in these areas.

With less fertilizers and pesticides, the quality of water may improve, and improvements in biodiversity may be seen which would impact the whole food chain.
The environmental benefits are vast, and it doesn’t stop there. By improving our environment, this may also have a knock-on effect with improvements in our health and wellbeing!

Enabling a better future for our environment

We at Pluri are hard at work to make this vision a reality. By combining our cell-based expertise through partnerships, we are seeking new approaches to accelerate development to create a better world for the generations to come.

However, true environmental change must come from the collective action of all of us. In the consumption choices we make here and now, as well as in the future. Only together can we build a more sustainable planet for our children.

As we honor World Environment Day, let’s remember there are billions of planets in the universe – but we have only one earth, one home.
Let’s make it the best it can be!

[1] Santo R. et al. Considering Plant-Based Meat Substitutes and Cell-Based Meats: A Public Health and Food Systems Perspective. Review Article:  Front. Sustain. Food Syst., 31 August 2020.

[2] Dopelt K. et al. Environmental Effects of the Livestock Industry: The Relationship between Knowledge, Attitudes, and Behavior among Students in Israel. Int J Environ Res Public Health. 2019 Apr; 16(8): 1359.

Key global challenges in sustainable development

Humans are the most populous large animal on earth today.  In fact, the average global human population grows by 2.6 people every second (81 million people per year).  That’s a lot of people and in fact, it means the world population could reach 8 billion by 2023!

At the same time, the number of people over 65 years of age is expected to double reaching 20% of the total population – a whopping 1.5 billion by 2050.  With more illnesses and long-term diseases as a result of aging and an associated poorer quality of life, global healthcare systems will face even greater resource pressures.

These rapidly changing dynamics mean we are now facing remarkable new global challenges. We are consuming, polluting and using more resources than ever before. Take conventional farming for example, we use more land and water to grow and raise food while also using fertilizers and pesticides that may contaminate and degrade the environment. On the other hand, we must also continue to provide healthcare with compassion and dignity for our aging population.

So how do we do this? The answer: changing the way we approach and solve these challenges. Innovation in cell-based products may provide the solution humanity needs.

Helping the planet with cell-based products

Cells are the building blocks of life. Our bodies are built from trillions of different cell types that work remarkably together in harmony to maintain our wellbeing.  In fact, life on earth begins and ends with cells. Yet the unique power of this tiny organism is only recently starting to be explored.

Over the last 15 years, we have seen considerable advances in biotechnology with breakthroughs in cell expansion and regenerative medicine. Cell therapies are important precisely because of the growing, aging population facing chronic and long-term diseases. We need to develop new solutions to regenerate and cure our bodies. This understanding led to considerable progress in the development of multiple cell-based therapies, as well as new and more effective biologics and improved approaches to regenerate damaged tissues.  Pluri’s placenta-based cell therapies are an example of these innovative products.

However, cell expansion technologies are not limited to the regenerative industry alone. This state-of-the-art technology has also led to new developments in emerging industries, for example in the food tech industry with cultured meat (genuine animal meat that is produced by cultivating animal cells directly).

With flavor similar to conventional food, cell-based meat production provides many advantages to support global sustainability.  For example, no animals are needed to be slaughtered meaning less land and water is used, fewer greenhouse gases, and a reduction in agriculture-related pollution demonstrate its environmental sustainability as well as ethical benefits with the elimination of animal cruelty.  Furthermore, cells can be altered to make food healthier, for instance, decreasing fats and increasing nutrients.

What is a cell-based product?

Cell-based products are products that contain or consist of cells or tissues from living tissue, whether human, animal, plant or fish cells that have been cultured and improved. At Pluri, we have developed a unique cell expansion platform to create various cell-based products.

Pluri’s state-of-the-art 3D cell expansion platform

Developed over the last decade, our state-of-the-art patented 3D cell expansion platform harnesses cutting-edge technologies in cell culture, tissue engineering and bioprocessing with the potential to expand and optimize cells of any type.

Our technology uses a proprietary bioreactor system, which provides a three dimensional (3D) micro-environment for our cells that is designed to mimic their natural environment.  The bioreactor is integrated into the one of the world’s most advanced, completely automated, aseptic and scalable cell manufacturing facilities.

This tightly controlled and efficient system means we can control every parameter, for example, temperature, glucose consumption and pH.  As such, the platform can alter conditions to provide cells with the most natural and optimal conditions for cell proliferation and expansion.

The bioprocessing know-how and design to scale-up

One of the biggest challenges facing cell manufacturing is scaling-up the technology for mass production.  At Pluri, we addressed this by designing and building from day one a bioprocessing approach with the capabilities to generate high-quality cell-based products on a mass scale in a cost-effective manner.

Our industrial scale GMP manufacturing facility hosts an in-house proprietary process development platform with exceptional capabilities.  This includes a proprietary serum-free media enabling highly consistent production without cost and operational reliance on third party suppliers.  The design and development of new manufacturing tools and devices, as well as cold chain methods and tools including Pluri’s Point-Of-Care Thawing Device.  For example, our advanced cold chain logistical capabilities support hundreds of cryopreserve cell shipments worldwide.

This validated and automated technology enables the production of billions of high-quality cells for mass-scale with batch-to-batch consistency.

Learning from Pluri’s pharma experience

Today, our technology applies the remarkable power of the placenta in the creation of new therapies for unmet medical needs where often no treatment exists today.

Our PLacental eXpanded (PLX) cell therapy can be administered without blood or tissue matching via a simple intramuscular injection. Our products provide potentially groundbreaking applications for treating damaged muscle, hematology deficiencies, and inflammation.

Our manufacturing processes are approved by key healthcare regulators and to date our PLX cells have treated hundreds of patients worldwide with a strong safety profile.

Harnessing cell-based products for a healthier planet

Yet, the power of Pluri’s cell-based manufacturing platform is not just limited to placental cells.  This broad, robust platform has much wider industry application. In fact, the technology can expand many different cell types, including human cells, animal cells, and even potentially plant cells.

By being able to control all parameters from upstream to downstream cell bioprocessing and produce cells on a mass scale with a low cost of goods, the platform can be harnessed to manufacture any cell type. This is not just important for every sector in the life science industry but brings much wider applications to other industries to address key global challenges.

As the pressing economic and healthcare challenges grow with an aging population, cell-based medical products offer new solutions to repair, regrow or replace damaged tissues and potentially cure diseases. As food, water and land resources must go further than ever before with a growing population, cell-based meat and plant-based meat production provide important solutions to maintain and ensure sustainability.

Partnering for greater success

So how do we make this potential better future a reality?

At Pluri, we believe in partnership. Combining expertise to enable the development of various new cell-based products for multiple applications across industries with global reach.

This can be seen with the recent signing of our landmark food-tech joint venture with Tnuva Group, Israel’s largest food producer, to establish a cultured food platform. This agreement supports Tnuva to expand their product pipeline into the field of cultured meat. While also leveraging Pluri’s state-of-the-art technology to address their cell manufacturing needs to produce cultured meat cells at scale for an affordable price.

From foodtech and agtech, to pharmaceuticals and other industries requiring mass cell production, the potential of Pluri’s technology is vast.

We are just at the beginning of exploring the microscopic universe of the cells.  So, tune into our upcoming blogs, as we step into this world of hope, wonder and opportunity.

Encouraging results from Pluri’s recent Phase 1 clinical trial not only give patients with bone marrow failure hope for a better recovery, but also reinforce the innovative cell therapy product candidate PLX-R18 as a potential treatment for radiation exposure.

The product candidate was tested in patients with incomplete hematopoietic recovery following hematopoietic cell transplantation (HCT), which may result in life-threatening failure of the bone marrow. Similarly, exposure to radiation can also result in bone marrow failure. This would mean that in the case of a nuclear fallout or other tragic radiation event, this therapy could be crucial for recovery.

The Dangers of Radiation

Even relatively low levels of radiation can cause immediate and irreversible damage to the human body, from altering our DNA to causing cancer. On the severe end of this spectrum is acute radiation syndrome (ARS), which causes potentially lethal damage to organs inside the human body.

One devastating manifestation of ARS is failure of the bone marrow, which leads to a reduction in its ability to produce blood cells. This may make victims of radiation exposure vulnerable to infections and bleeding.

ARS, therefore, is a life-threatening disorder.

Unfortunately, radiation exposure is a very real risk in our world today. Healthcare providers and governments are preparing for the devastating possibility of a nuclear attack or damage to existing facilities. Our therapy carries great potential significance for current events in Europe and could potentially provide treatment for people exposed to radiation.

Treating Acute Radiation Syndrome

Pluri’s research studies evaluated PLX-R18 as a medical countermeasure either before or after exposure to radiation, and gained support from multiple U.S. governmental agencies, including the National Institutes of Health (NIH) and the Department of Defense (DoD). These agencies conducted and funded the studies to PLX-R18 as a medical countermeasure to treat the hematopoietic sub-syndrome of ARS, and as a potential prophylactic countermeasure against ARS.

All our studies tested PLX-R18 via the FDA animal rule pathway, as efficacy studies are not permitted in humans for this therapy. After our promising pilot study on non-human primates, our PLX cell therapy was granted an orphan drug designation by the FDA for treating ARS.

The Orphan Drug Act provides granting special status to a drug or biological product, to treat a rare disease or condition. The benefits of achieving Orphan Drug Designation include close guidance by the FDA—which may accelerate the path to potential marketing approval—orphan drug grants, tax credits, and 7-year market exclusivity upon marketing approval.

One year later, the FDA cleared Pluri’s Investigational New Drug (IND) application for PLX-R18 for the treatment of ARS. This special application allows for the treatment of victims acutely exposed to high dose radiation due to a nuclear attack or accident.

PLX-R18 Hematology Updates

In our Phase I clinical study in patients with poor graft function following HCT, we showed positive results for the innovative therapy in the first clinical trial to study PLX-R18 in humans. Pluri CEO and President Yaky Yanay called it “a game changer.”

Current standard-of-care treatments do not lead to a satisfactory, long-term blood count stabilization, leading to recurrent infections and the need for repeated, costly blood transfusions. PLX-R18, on the other hand, is well tolerated by patients, shows a meaningful advantage as it reduces mortality from 29 to 18%, increases blood counts, and reduces the need for blood transfusions.

“We are proud of this product that might hold the key to improve quality of life, improve standard of care, save healthcare costs and possibly save lives,” Yanay said. He goes on to explain how PLX-R18 can accelerate hematopoietic recovery in sick patients, increase blood counts and reduce the need for blood transfusions.

These additional studies of PLX-R18 in both ARS and other hematological trials were conducted in collaboration with Charité Universitätsmedizin Berlin Institute of Medical Immunology, the Berlin-Brandenburg Center for Regenerative Therapies, Case Western Reserve University, Hadassah Hebrew University Medical Center, and Indiana University. All studies supported PLX-R18’s therapeutic potential to treat a variety of hematologic issues.

Pluri will continue to push the boundaries of science and engineering to create cell-based products for commercial use and improve the quality of life of people around the world.

In a press release dated April 29, 2021, we reported positive topline Phase I results in our innovative hematology program. This study, the first to evaluate PLX-R18 in humans, demonstrated that PLX-R18 had the potential to stimulate the bone marrow to generate all three blood cell lines – a meaningful advantage over other existing and proposed treatments.

The Problem:

Blood disorders can be very challenging to manage. Consider, for example, a cancer patient suffering from Acute Lymphoblastic Leukemia (ALL), who is receiving a Hematopoietic Cell Transplantation (HCT). While the transplant itself can improve his chances of survival from the cancer, there is a potential risk of poor graft function resulting in incomplete hematopoietic recovery leaving the patient with a life-threatening condition. Between 5-10% of all HCT recipients suffer from poor graft function (source: Chen 2020).

While standard-of-care treatments may temporarily improve blood counts, patients that continuously fail to maintain satisfactory blood counts may remain vulnerable to bleeding and recurrent infections. These patients will require repeated, costly blood transfusions, which are, unfortunately, only a short-term solution.

Therefore, we believe that there is a need for long-lasting treatment that has the potential to support generation of all three blood lines, red blood cells, white blood cells and platelets, thereby alleviating the dependency on blood transfusions and medications. Current standard of care does not address all three blood lines at once. Rather, patients suffering from sub-optimal bone marrow recovery may need to receive multiple treatments to address each deficiency.


Our PLX cells are derived from placentas that have been donated by women after birth. The PLX cells release a range of therapeutic proteins that trigger the body’s regenerative mechanism in response to severe medical conditions. PLX-R18 is the first product candidate manufactured using Pluri’s proprietary serum-free media in a 3-D bioreactor system, displaying our unique capability to manufacture a high quantity of cells with batch-to-batch consistency. Created from cells that originated from the fetus side of the placenta, PLX-R18 is unique in its potential to support renewal and differentiation of hematopoietic cells.

Our hematology program tested the use of PLX-R18 in HCT recipients. We were pleased to find that the PLX-R18 showed promising results. The study enrolled 21 patients in the U.S. and Israel, who were at least three months after the HCT procedure (median: 236 days) and had low blood counts in at least one blood cell lineage. They were assigned to one of three treatment arms: 1 million cells/kg, 2 million cells/kg, or 4 million cells/kg. Each patient received two treatments of the assigned dose.

The results, which included data from 14 of the 21 patients*, demonstrated that PLX-R18 had the potential to stimulate the implanted hematopoietic cells to realize their therapeutic potential and generate improved blood counts over the long term in all three blood cell lines at once – a meaningful advantage over other existing and proposed treatments. Overall, PLX-R18 was well tolerated and showed significant improvements from baseline counts in all cohorts for hemoglobin and platelet counts. Interestingly, patients in the high-dose category exhibited statistically significant improvements in all three blood cell lines.

Moving Forward:

Pluri’s Chief Medical Officer, Nitsan Halevy, believes that these results are an important step for the science of blood, or hematology. PLX-R18’s proposed hematopoietic mechanism of action, now demonstrated for the first time in humans in our Phase I HCT study, potentially opens up new therapeutic options in the fields of hematology. Building on these encouraging initial results, Pluri is refining its clinical development plans for PLX-R18 to address areas of unmet medical need.

* Data from the six-month follow-up is available for 14 of the 21 treated patients: one patient was terminated early, three patients missed the 6-month visit and three died prior to the 6-month visit (two fatal events in the 2 million cell dose, and one fatal event in the 4 million cell dose). All fatal events in the study were considered unrelated to the study treatment. Mortality rates were in line with publicly available information (references: Gao et al 2020, Halahleh et al 2021, Tang et al 2018, Sun et al. 2015, Zhao et al 2019)

Terms of use

Use of the Pluri Web Site


Pluri Biotech Ltd., on its behalf and on behalf of its related companies, including without limitations, its parent company, Pluri Inc. (collectively: “Pluri”) maintains [] (this “Website”) for informational purposes in favor of the Internet community. Access to and use of information presented on this Website is subject to the following terms and conditions which may be revised at any time by Pluri and to the Privacy Notice located on this Website and incorporated hereto by reference.

The information contained in these pages is not intended to provide medical advice, recommendation or instruction on the appropriate use of Pluri’s technology, nor that Pluri technology is marketable nor fit for a particular purpose.  In addition, nothing herein shall be deemed as solicitation for purchasing any of Pluri’s securities.

Please read carefully the following terms and conditions. The use of this Website is governed by these terms and conditions and our Privacy Policy, By using and accessing this Website, you agree to be bound by these terms of use including any amendments that may be made by Pluri from time to time at its sole discretion. Pluri encourages the users of this Website to periodically review these terms of use for any changes or amendments.

Forward-Looking Statements; SEC / TASE Filings

Pluri Inc., is a public company, which securities are traded on the Tel Aviv Stock Exchange (TASE) and Nasdaq.  Statements on this Website regarding Pluri’s business which are not historical facts are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws, that involve risks and uncertainties. Forward-looking statements can be identified by, among other things, the use of forward-looking language, such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “future”, “intend”, “plan”, “potential”, and may describe opinions about future events. These forward-looking statements are based on the current expectations of the management of Pluri only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching our clinical trials; our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our progress; our products may wind up being more expensive than we anticipate; results in the laboratory may not translate to equally good results in real surgical settings; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluri to differ materially from those contemplated in such forward-looking statements. For a more detailed description of the risks and uncertainties affecting Pluri, reference is made to Pluri’s reports filed from time to time with the Securities and Exchange Commission (“SEC”). Pluri disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. No information or statement in this website is intended to solicit in any manner whatsoever any person to purchase or deal in any securities of Pluri. Pluri may provide links to its filings with the SEC for informational purposes only, and not for trading or investment purposes. Pluri does not guarantee the sequence, accuracy or completeness of any information or data displayed through these links. Pluri does not assume any duty of disclosure and expressly disclaims any duty to update information set forth in its filings with the SEC.  The stock price performance shown on stock quotes may be available on or through this Website is not necessarily indicative of future price performance. All content is for informational purposes only and no content is intended to be relied upon for trading or investment purposes. Nothing on this website constitutes an invitation or offer to invest or deal in the securities of Pluri. In particular, actual results and developments may be substantially and materially different from any opinion or forecast expressed on this website.

Links to Third Party Websites

The Website may provide links to World Wide Web sites or resources. Because Pluri has no control over such sites and resources, you acknowledge and agree that Pluri is not responsible for the availability of such external sites or resources, and does not endorse and is not responsible or liable for any information, advertising, products, or other materials on or available from such sites or resources. You further acknowledge and agree that Pluri shall not be responsible or liable, directly or indirectly, for any damage or loss caused or alleged to be caused by or in connection with use of or reliance on any such information, goods or services available on or through any such site or resource.


Within the course of your use of the Website you will strictly adhere with the following policies, such that, you must not:

·         Scan or use this Website via operation of a computer program designed to gather information or perform operations imitating a human user (including, without limitation, Bots or Crawlers);

·         Manipulate the architecture of this Website, or otherwise gain access to any of its engines and/or databases to which we did not provide you with an expressly permitted access (including, without limitation, URL Hacking);

·         Carry out any action which may infringe the copyrights and/or any other proprietary information of ours or any other copyright holder;

·         Copy, transmit, decompile, modify, create derivative works, reproduce, disassemble, republish, scrape, and/or reverse engineer (including any extraction of the work process) any algorithm, code, syntax and/or any other content associated with this Website and/or any components thereof and/or act to collect, harvest and/or data mine any data associated with the Website and/or any of its users (whether by computer programs, identity theft, impersonation, or otherwise) and/or take any action which may be deemed as impersonating another person or entity, identity theft, etc.;

·         Carry out any action which may infringe any laws, regulations, orders or any guidelines of any governmental authority, is likely to offend or harm any other users of this Website and/or the general public;

·         Steal or attempt to steal private information from other users of this Website;

·         Email us content which is or could be considered libelous, defamatory, indecent, vulgar, obscene, pornographic, sexually explicit or suggestive, racially or ethically offensive, harmful, harassing, intimidating, threatening, discriminatory, or abusive;

·         Carry out any action that violates these Terms, Privacy Notice and/or any other guidelines or policies as prescribed herein and/or as otherwise published by us from time to time.

·         Assist, encourage or enable others to do any of the preceding prohibited activities.

Intellectual Property Rights

You acknowledge that Pluri owns all copyrights in the information, selection, coordination, arrangement and enhancement of this Website, which may contain information, software, photos, video, text, graphics, or other material posted or uploaded by Pluri (collectively, the “Pluri Content”), and that these rights are valid and protected in all forms, media and technologies existing now or here after developed. Pluri has the full rights and authorization to use this Website’s name and logo. You may not modify, publish, transmit, participate in the transfer or sell, create derivative works, or in any way exploit, any of the Pluri Content, in whole or in part. Modification of the Pluri Content or use of any Pluri Content on any other website, networked computer environment or elsewhere is strictly prohibited. The Pluri Content is subject to copyright protection. You may not copy the contents of this Website other than for non-commercial individual reference with all copyright or other proprietary notices retained, and thereafter the contents may not be recopied, reproduced or otherwise redistributed. You may not distribute, modify, repost, copy, publish license or use the contents of this website, including information, photos, video, text, graphics or other material posted or upload by Pluri for public or commercial purposes. Some of the tradenames or trademarks used in this Website are registered trademarks of Pluri and/or its affiliates. The use or misuse of any of these trademarks or unregistered trademarks or any other materials, except as permitted herein, is expressly prohibited and may result, inter alia, in violation of copyright laws and trademark laws.

Subject to any applicable terms and conditions set forth in our Privacy Notice, any communication or other material that you send to us through the Internet or post on the Website by electronic mail or otherwise, such as any questions, comments, suggestions or the like, is and will be deemed to be non-confidential and we shall have no obligation of any kind with respect to such information. Pluri shall be free to use any ideas, concepts, know-how or techniques contained in such communication for any purpose whatsoever, including but not limited to, developing, manufacturing and marketing products.



Limitation of Liability




You agree to indemnify, defend and hold harmless Pluri, its officers, directors, shareholders, employees, sub-contractors, affiliates, agents and anyone acting on their behalf, at your own expense and immediately after receiving a written notice from Pluri, from and against any damages, loss, costs, expenses and payments, including reasonable attorney’s fees and legal expenses, resulting from any complaint, claim, or demand, arising from or related to your breach of these terms of use, or any other terms, rules or regulations applicable to this website, or your violation, or infringement of other persons rights.


Governing Law. These terms of use shall be governed in accordance with the laws of the State of Israel without giving effect to any conflicts of law principles. Any dispute in connection with these terms of use shall be submitted to the exclusive jurisdiction of the competent courts situated in Tel Aviv, Israel.

Entire Agreement. These terms and conditions contain the entire agreement between the parties with respect to the subject matter hereof, and supersede all prior and contemporaneous representations, promises, agreements and understandings, whether oral or written, between the parties concerning the subject matter hereof.

Severability. If any provision of these terms of use shall be deemed to be invalid, void, illegal or for any reason unenforceable, that term or condition shall be deemed severable and shall not affect the validity and enforceability of the remaining terms set forth herein. Subject to any applicable law, all disputes between you and us shall only be resolved on an individual basis and you shall not have the right to bring any claim against us as a plaintiff or a member of a class, consolidated or representative actions (or any other legal proceedings conducted by a group or by representatives on behalf of others).

Assignment. You may not assign any rights and/or obligations you may have under these terms and conditions and/or Privacy Notice without our prior written consent. We may freely assign any of its rights and/or obligations herein, without limitations; provided that, your rights herein shall not be adversely affected.

Change of Control. It is clarified that in the event of a merger, change of control and/or any similar transaction involving Pluri, Pluri may transfer and export all information it may have gained through the course of the use of the Website, and your use of this Website constitutes as consent for the foregoing; provided however, that any such transfer shall be subject to applicable data privacy requirements and standards.

Amendment. Pluri reserves the right to amend or revise any of these terms of use. Any such change or amendment shall be updated on this Website.

The content, text, graphics, data, and services offered herein are provided solely to educate users of this Website on Pluri and the goods and/or services it may provide.  Nothing in said content should be considered, or used as a substitute for, medical advice, diagnosis or treatment.  Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.  Reliance on said content or any portion thereof, or other visitors to the web site, is solely at your own risk.

If you have cause to believe any content found on the Platform to be in violation of these terms and conditions and/or infringe any third party proprietary rights and/or applicable law, kindly notify us of such content via email to,  stating the violating content and the nature of violation.

Physical address:  Matam Park, Building 05, Haifa, 3508409, Israel


Accessibility Statement

Pluri Biotech Ltd. is committed to making its electronic and information technologies accessible to individuals with disabilities by meeting or exceeding the requirements of the Web Content Accessibility Guidelines and we make every effort to ensure our communications – including this website – are accessible to people with special needs.

We have striven to make this website adhere to priority 1 and 2 guidelines of the W3 Web Content Accessibility Guidelines.


Navigation and navigation aids

  • The full site navigation is located on every page.
  • A link to the home page is available on each page.
  • Navigation menus are marked up as HTML lists and styled with CSS.
  • Some links have title attributes, which describe the link in greater detail. Most links are self-explanatory.
  • Links are written so as to make sense out of context.
  • Some links, mostly to downloadable files such as PDFs, open a new browser tab.

Help with finding content

Although we do our best to meet the requirements and guidelines, it is possible that some of the content is not yet fully accessible and compatible to people with special needs.

We continue to develop and improve our website as part of our general commitment to make every effort to ensure our communications are accessible to all.
If you require assistance or wish to report an issue related to the accessibility of any content on this website, please contact If applicable, please include the web address or URL and the specific problems you have encountered.

Pluri – Privacy Policy

Last updated on 26 December 2022

  1. Introduction

Pluri Biotech Ltd., on its behalf and on behalf of its related companies (“Pluri” “we” or “us”) respects the privacy of its participants, employees, sites visitors and website visitors (these and any others with respect to whom we collect personal data, shall collectively be referred to as “you” or “Data Subjects”) and is committed to protecting the personal information you may share with us.

This policy and notice (the “Privacy Policy”) explains the types of information we may collect from you, that we may receive about you or that you may provide during your participation in our services, business transactions, conferences or when you visit our sites or website. We are transparent about our practices regarding the information we may collect, use, maintain and process and describe our practices in this Privacy Policy. Please read the following carefully to understand our practices regarding your personal data and how we will treat it.

What is Personal Data?

Regarding our relations with you in connection with your use of our services, “Personal Data” means any data, which may enable the identification of a specific person, or is otherwise linked to such potentially identifying data.

  1. For What Purposes Do We Collect Your Personal Data?

We will use your Personal Data to provide and improve our services to our participants and others and meet our contractual, ethical and legal obligations. All Personal Data will remain accurate complete and relevant for the stated purposes for which it was processed, including for example:

Processing which is necessary for the performance of a contract to which you are a party or in order to take steps at your request prior to entering into a contract:

  • Carrying out our obligations arising from any contracts entered into between you and Pluri and to provide you with the information, and services that you request from Pluri.

Processing which is necessary for the purposes of the legitimate interests pursued by Pluri:

  • Notifying you about changes to our terms;
  • Contacting you for the purpose of providing you with technical assistance and other related information about the services;
  • Replying to your queries, troubleshooting problems, detecting and protecting against error, fraud or other criminal activity;
  • Contacting you to give you commercial and marketing information about events or promotions or additional services and products offered by Pluri, including in other locations;
  • Soliciting feedback in connection with your use of the services;
  • Tracking use of Pluri facilities and services to enable us to optimize them;
  • Contacting you to inform you of additional services which may be of interest to you;

Processing which is necessary for compliance with a legal obligation to which Pluri is subject:

  • Compliance and audit purposes, such as meeting our reporting obligations in our various jurisdictions, and for crime prevention and prosecution in so far as it relates to our staff, participants, facilities etc.
  • If necessary, we will use Personal Data to enforce our terms, policies and legal agreements, to comply with court orders and warrants and assist law enforcement agencies as required by law, to collect debts, to prevent fraud, infringements, identity thefts and any other service misuse, and to take any action in any legal dispute and proceeding;
  • For security purposes and to identify and authenticate your access to the parts of the facilities;

Non-Personal Data. We may share or otherwise use non-Personal Data in our sole discretion and without the need for further approval.


  1. How Do We Collect Your Data?

We collect two main categories of Personal Data:

  1. Data Received From You.We collect Personal Data required to provide services when you register interest, or when you provide us such information by entering it manually or through your use of our website, facilities and services, or in connection with site visits, in the course of preparing a contract, or otherwise in engaging with us. We also may collect Personal Data when you call us for support, in which case we collect the information you provide us. We also collect Personal Data through our CCTV recordings which automatically collect information about your presence in the Pluri facilities. You may provide us Personal Data voluntarily, such as your name, e-mail address, phone number, and location when you contact us. We urge you not to share any medical or other related sensitive information with us when communicating with us unless specifically requested by us for the services. Regardless of our data retention policies, we may remove from our records, at any time, any such sensitive information.
  2. Data Automatically Collected or Generated Through Your Use of Our website. When you visit, interact with or use our website, including any e-mail sent to you by us, we may collect or generate technical data about you. We collect or generate such data either independently or with the help of third-party services, including through the use of cookies and other tracking technologies (as further detailed in our ‘cookies’ section below). Such data consists of connectivity, technical or aggregated usage data, such as IP address, non-identifying data regarding the device, operating system, browser version locale and language settings used, the cookies and pixels installed on such device, and the activity (clicks and other interactions) of users of our website.

If you choose to give us your e-mail address, we will communicate with you via e-mail. We do not share your e-mail address with other individuals, entities and/or parties outside of Pluri. Depending on how your email application is set up, information about your actions, use of the email sent by us, may be transmitted automatically when you receive, open and/ or click on an e-mail from Pluri. In any event, you may opt out from receipt of any additional e-mails from Pluri, at any time.


  1. Website Data Collection and Cookies

When you access or use our services or website, Pluri may use industry standard technologies such as cookies, pixels and similar technologies, which store certain information on your computer or browsing device and which will allow us to identify the computer or device and, in some cases, to identify them with the user, and to enable automatic activation of certain features, and make your user experience more convenient and effortless. We use different types of cookies: some cookies are strictly necessary, they are required for the operation of our website and services under our terms with you; We also use analytical and performance monitoring cookies, which allow us to recognize and count the number of visitors and to see how visitors move around our website and services when they are using it. Finally, we use functionality cookies which are used to recognize you when you return to our website. This enables us to personalize content to your preferences, including for example, your choice of language or region.

Different cookies are kept for different periods. Session cookies are used to keep track of your activities online in a given browsing session; these cookies generally expire when the browser is closed but may be retained for a period on your device. Permanent cookies remain in operation even when you have closed the browser; they are used to remember your login details and password. Third-party cookies are installed by third parties with the aim of collecting certain information to research behavior, demographics. Third party cookies on our site include, for example, Google Analytics. Likewise, pixels from Youtube and others enable integration of third-party service providers may be embedded on our site. Third party cookies will be retained according to the terms of those third parties, and you can control those cookies in your browser settings.

We use cookies and other technologies on the basis that they are necessary for the performance of a contract with you, or because using them is in our legitimate interests of improving, optimizing and personalizing our services, and these are not overridden by your rights.

Most browsers will allow you to erase cookies from your computer’s hard drive, block acceptance of cookies, or receive a warning before a cookie is stored. However, if you block or erase cookies your online experience on our websites and services will be limited.

How to disable cookies: the effect of disabling cookies depends on which cookies you disable but, in general, the websites and some services delivered through them may not operate properly, may not recognize your device, may not remember your preferences and so on, if cookies are disabled or removed. However, allowing or disabling cookies is your choice and in your control. If you want to disable cookies on our site, you need to change your browser settings to reject cookies. How you can do this will depend on the browser you use. Further details on how to disable cookies can be found here: Microsoft EdgeGoogle ChromeFirefoxSafari.

  1. How Do We Retain and Store Your Data?

Pluri Biotech Ltd. is located and operates under the jurisdiction of the State of Israel, which has been declared by the European Commission, on the basis of Article 45 of Regulation (EU) 2016/679 as a country outside the European Union (the “EU”) which offers an adequate level of data protection.

Company’s parent, Pluri Therapeutics Inc. is a Nevada-based corporation, and thus abides by the applicable U.S. privacy law; however, it has also taken upon itself, to adopt additional security measures regarding the storage of your Personal Data, and only to use it in accordance with this Privacy Policy.

While privacy laws may vary between jurisdictions, Pluri has taken reasonable steps to ensure that your Personal Data is treated by its affiliates and Service Providers in a secure and lawful manner, and in accordance with common industry practices, regardless of any lesser legal requirements that may apply in their jurisdiction.

Pluri retains Personal Data it processes only for as long as required in our view, to provide the services and as necessary to comply with our legal and other obligations, to resolve disputes and to enforce agreements. We will also retain personal data to meet any audit, compliance and business best-practices.

Data that is no longer retained may be anonymized or deleted. Likewise, some metadata and statistical information concerning the use of our services are not subject to the deletion procedures in this policy and may be retained by Pluri. We will not be able to identify you from this data. Some data may also be retained on our third-party service providers’ servers until deleted in accordance with their privacy policy and their retention policy.

Please note that except as required by applicable law, we will not be obligated to retain your data for any particular period, and are free to securely delete it for any reason and at any time, with or without notice to you.

  1. With Whom Do We Share Data?

We may share your data (including Personal Data) with certain third parties, including law enforcement agencies, our service providers, and our affiliates – but only in accordance with this Privacy Policy:

  1. Compliance with Laws, Legal Orders and Authorities.We may disclose or allow government and law enforcement officials access to certain Personal Data, in response to a subpoena, search warrant or court order (or similar requirement), or in compliance with applicable laws and regulations, including for national security purposes. Such disclosure or access may occur with or without notice to you, if we have a good faith belief that we are legally compelled to do so, or that disclosure is appropriate in connection with efforts to investigate, prevent, or take action regarding actual or suspected illegal activity, fraud, or other wrongdoing.
  2. Service Providers and Business Partners.We may engage selected third-party companies and individuals to perform services complementary to our own (hosting services, data analytics services, media sources, e-mail distribution and monitoring services, and our business, legal, financial and compliance advisors) (collectively: “Service Providers”). These Service Providers may have access to your Personal Data, depending on each of their specific roles and purposes in facilitating the goals of our website, and may only use it for such purposes. A list of the Service Providers we currently engage that have access to your Personal Data can be viewed
  3. Protecting Rights and Safety. We may share your Personal Data with others, if we believe in good faith that this will help protect the rights, property or personal safety of Pluri, any of our users or any members of the general public.
  4. Security Measures

Pluri maintains physical, electronic and procedural safeguards to help guard your Personal Data. We restrict access to personally identifiable information to those persons who need to know that information to provide products or services to you and any persons you have authorized to have access to such information. While we strive to protect your Personal Data, we cannot guaranty the security of any information you transmit to us.

Pluri shall act in accordance with its policies and with applicable law to promptly notify the relevant authorities and data subjects in the event that any Personal Data processed by Pluri is lost, stolen, or where there has been any unauthorized access to it, all in accordance with applicable law and on the instructions of qualified authority. Pluri shall promptly take reasonable remedial measures.

  1. Transfer of Personal Data Between the Pluri Group Entities / Service Providers

We may allow access to your Personal Data for the uses prescribed in this Privacy Policy, internally, between our group entities. In instances where Personal Data is collected from individuals within the EU, we will make sure that for the transfer outside EU borders (a) an EU Commission Adequacy Decision is in place, or (b) we have a legitimate interest of such transfer, and the recipient entity is bound by similar security measures that we apply, and further subject to the provisions of Section 5.

  1. EU Data Subject Rights Regarding Personal Data under GDPR

Please note that you may have certain rights regarding the manner of collection, processing and usage of your Personal Data pursuant to applicable privacy laws such as the EU General Data Protection Regulations (“GDPR”). Under the GDPR (to the extent it applies to you) you may be eligible for the following rights:

  • Right to Access. You have a right to access your personal data that we process and receive a copy of it.
  • Right to Rectification. You have the right to ask us to rectify inaccurate personal data concerning you and to have incomplete personal data completed.
  • Right to Data Portability. You have a right to receive the personal data that you provided to us, in a structured, commonly used and machine-readable format. You have the right to transmit this data to a third party. Where technically feasible, you have the right that your personal data be transmitted directly from us to a third party that you designated.
  • Right to Withdraw Consent. You have the right to withdraw your consent for processing your personal data at any time. If you do that, we will not collect any further personal data, but we will further process the data we already collected for reasons described in this Policy. Withdrawing your consent will not affect the lawfulness of data processing we carried out based on your consent before such withdrawal.
  • Right to Object. If you previously agreed that your personal data may be used for other purposes other than registering and/or placing an order, you may have a right to object to the use of your personal data for such additional purposes.
  • Right to Restrict. You have the right to restrict processing of your Personal Data (except for storing it) if you contest the accuracy of your Personal Data, for a period enabling us to verify its accuracy; if you believe that the processing is unlawful and you oppose the erasure of the Personal Data and request instead to restrict its use; if we no longer need the Personal Data for the purposes outlined in this Policy, but they are required by you to establish, exercise or defense relating to legal claims, or if you object to processing, pending the verification whether our legitimate grounds for processing override yours.
  • Right to be Forgotten. Under certain circumstances, such as when you withdraw your consent, you have the right to ask us to erase your Personal Data. However, we may still process your Personal Data if it is necessary to comply with a legal obligation we are subject to under the laws in EU Member States.

Please note that the above list contains a summary of the main rights you may have under the GDPR. Under no circumstances shall the above be deemed as an exhaustive list, nor should you rely on it in terms of fully understanding all of your rights under the GDPR.

Additional Information for users entitled to rights under GDPR:

EU Representative. Our European representative, for the purposes of this Privacy Policy, is Pluri GmbH. If you are within the European Economic Area, you may contact our European representative at the following address: Brentanoweg 9, 14469 Potsdam, Germany, or by email address:

If you believe your right have been infringed, you can lodge a complaint with a supervisory authority operating under the GDPR. For a list of supervisory authorities in the EU, click here.

  1. Children

This website is directed towards and designed for use by persons aged 18 and older. We do not solicit or knowingly collect Personal Data from children under the age of 18. If we nevertheless receive Personal Data from an individual who indicates that he or she is, or whom we otherwise have reason to believe is, under the age of 18, we will delete such information from our systems.

  1. Links to Third Party Websites

The website may contain links to other websites. While we try to link only to websites that share our respect for privacy, please be aware that Pluri is not responsible for the privacy practices or the content of other websites. Websites that are accessible by hyperlinks from our website may use cookies. We encourage you to read the privacy statements provided by other websites before you provide personally identifiable information to them.

  1. Changes to this Privacy Policy

This Privacy Policy may change over time as we modify or expand our service. If we decide to change our Privacy Policy, we will prominently post those changes on this page. Your continued use of this website after we post such notice constitutes your agreement to any such changes.

  1. Contacting Us

If you have any questions about this Privacy Policy, or in the event that you wish to exercise certain rights you are eligible for with respect to your Personal Data, please contact us via the below online contact form. We welcome your questions and suggestions about our Privacy Policy.

Contact Information:

By mail:

(Kindly state the nature of your inquiry at the subject line of the email)

Physical address:

Pluri Biotech Ltd.

Attention: General Counsel and DPO

Matam Park, Building 05

Haifa, 3508409, Israel

©2023 Pluri Inc.

©2023 Pluri Inc., its logo, brand, product, and process names appearing in this issue are the trademarks of Pluri™ Inc. or its affiliated companies. All other brand, product, and process names appearing are the trademarks of their respective holders. Reference to or use of a product, or process other than those of Pluri™ Inc. does not imply recommendation, approval, affiliation, or sponsorship of that product, or process by Pluri™ Inc. Nothing contained herein shall be construed as conferring by implication, estoppel, or otherwise any license or right under any patent, copyright, trademark, or other intellectual property right of Pluri™ Inc. or any third party, except as expressly granted herein.  All information herein is for general information only and is subject for change without notice.



Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.